2022
Novel pathophysiological insights in autoimmune myasthenia gravis
Masi G, O’Connor K. Novel pathophysiological insights in autoimmune myasthenia gravis. Current Opinion In Neurology 2022, 35: 586-596. PMID: 35942663, PMCID: PMC9458626, DOI: 10.1097/wco.0000000000001088.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAutoimmune myasthenia gravisMyasthenia gravisMG patientsClinical responseMuscle-specific tyrosine kinaseSpecific therapeutic strategiesNovel pathophysiological insightsMG pathologyMG subtypesAutoantibody repertoireTreatment optionsCancer immunotherapyPredictive biomarkersSuch therapyImmunological heterogeneityPathophysiological insightsMG phenotypeTherapeutic strategiesClinical observationsTherapeutic outcomesAcetylcholine receptorsDisease subtypesTherapeutic perspectivesSubtypesDevelopment of assays
2020
The B cell immunobiology that underlies CNS autoantibody-mediated diseases
Sun B, Ramberger M, O’Connor K, Bashford-Rogers RJM, Irani SR. The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nature Reviews Neurology 2020, 16: 481-492. PMID: 32724223, PMCID: PMC9364389, DOI: 10.1038/s41582-020-0381-z.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoantibodiesAutoantigensAutoimmune DiseasesB-LymphocytesCentral Nervous System DiseasesHumansImmunotherapyConceptsAutoantigen-specific B cellsB cellsPathogenic autoantibodiesB cell tolerance checkpointsAutoantibody-mediated diseasesB cell immunobiologyLong-term morbidityHigher serum levelsCirculation of patientsSource of autoantibodiesSite of pathologyB-cell lineageClinical relapseAvailable medicationsSerum levelsIntrathecal synthesisCNS diseaseTolerance checkpointsPlasma cellsTherapeutic effectCerebrospinal fluidGerminal centersAutoantibodiesDiseasePatients
2017
B cells in the pathophysiology of myasthenia gravis
Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O’Connor K. B cells in the pathophysiology of myasthenia gravis. Muscle & Nerve 2017, 57: 172-184. PMID: 28940642, PMCID: PMC5767142, DOI: 10.1002/mus.25973.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyasthenia gravisB cellsMuscle-specific tyrosine kinaseArchetypal autoimmune diseaseMuscle end platesProduction of autoantibodiesMost patientsPathogenic autoantibodiesAutoimmune diseasesAdaptive immunityHuman studiesAcetylcholine receptorsFunctional AChRsNeuromuscular junctionPostsynaptic proteinsAutoantibodiesCellular immunologyMolecular immunologyGravisImmunopathologyPathologyAChRImmunologyTyrosine kinaseEnd plates
2016
Chapter 27 Current and future immunotherapy targets in autoimmune neurology
Hu MY, Stathopoulos P, O’connor K, Pittock SJ, Nowak RJ. Chapter 27 Current and future immunotherapy targets in autoimmune neurology. Handbook Of Clinical Neurology 2016, 133: 511-536. PMID: 27112694, DOI: 10.1016/b978-0-444-63432-0.00027-x.ChaptersConceptsAutoimmune neurologic disordersNeurologic disordersChronic inflammatory demyelinating polyradiculoneuropathyInflammatory demyelinating polyradiculoneuropathyPrior treatment responseLarge case seriesAbsence of cancerAutoimmune neurologyChronic immunotherapyDemyelinating polyradiculoneuropathyMyasthenia gravisNeuromyelitis opticaCase seriesOncologic therapyTreatment trialsImmunotherapy targetClinical severityTreatment strategiesTreatment responseAntibody typeMonoclonal antibodiesAnecdotal reportsNew drug discoveryDisordersImmunotherapy